Treating oral cancer with targeted therapy drugs: from beginning to bench-side

Yao Huang

doi:10.1117/12.2670386

24 March 2023 Treating oral cancer with targeted therapy drugs: from beginning to bench-side

Yao Huang

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126116G (2023) https://doi.org/10.1117/12.2670386
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

Sarcomas are the deadliest tumors of the mouth and jaw. Among all the oral cancers, squamous cell carcinoma is one of the most common tumors. It is responsible for more than 80% of all cancers. Thus, attention and healthcare should be paid in the aspects of oral cancer and its treatment, especially for epithelial and squamous cell carcinomas. In this scenario, recent progression for oral cancer treatment is in great demand for analysis and comparison. As a major breakthrough in cancer treatment, targeted therapy has remarkable potential to replace traditional treating options.

Citation Download Citation

Yao Huang "Treating oral cancer with targeted therapy drugs: from beginning to bench-side", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126116G (24 March 2023); https://doi.org/10.1117/12.2670386

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available